JOP20220014A1 - ملح وصور بلورية لمثبط كيناز شبيه بمستقبل أكتيفين - Google Patents

ملح وصور بلورية لمثبط كيناز شبيه بمستقبل أكتيفين

Info

Publication number
JOP20220014A1
JOP20220014A1 JOP/2022/0014A JOP20220014A JOP20220014A1 JO P20220014 A1 JOP20220014 A1 JO P20220014A1 JO P20220014 A JOP20220014 A JO P20220014A JO P20220014 A1 JOP20220014 A1 JO P20220014A1
Authority
JO
Jordan
Prior art keywords
salt
kinase inhibitor
crystal forms
activin receptor
activin
Prior art date
Application number
JOP/2022/0014A
Other languages
Arabic (ar)
English (en)
Inventor
Harald Ohmer
Steven C Johnston
Dominik Siegel
Debra Mazaik
Lauren Maceachern
Clare Medendorp
Brian Heinrich
Joshua D Waetzig
Gordon Wilkie
Original Assignee
Blueprint Medicines Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blueprint Medicines Corp filed Critical Blueprint Medicines Corp
Publication of JOP20220014A1 publication Critical patent/JOP20220014A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JOP/2022/0014A 2019-08-13 2020-08-12 ملح وصور بلورية لمثبط كيناز شبيه بمستقبل أكتيفين JOP20220014A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962885977P 2019-08-13 2019-08-13
PCT/US2020/045847 WO2021030386A1 (en) 2019-08-13 2020-08-12 Salt and crystal forms of an activin receptor-like kinase inhibitor

Publications (1)

Publication Number Publication Date
JOP20220014A1 true JOP20220014A1 (ar) 2023-01-30

Family

ID=72193669

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2022/0014A JOP20220014A1 (ar) 2019-08-13 2020-08-12 ملح وصور بلورية لمثبط كيناز شبيه بمستقبل أكتيفين

Country Status (15)

Country Link
US (1) US20220281879A1 (cg-RX-API-DMAC10.html)
EP (1) EP4013757A1 (cg-RX-API-DMAC10.html)
JP (2) JP7775186B2 (cg-RX-API-DMAC10.html)
KR (1) KR102967623B1 (cg-RX-API-DMAC10.html)
CN (2) CN114222745B (cg-RX-API-DMAC10.html)
AU (1) AU2020328534B2 (cg-RX-API-DMAC10.html)
BR (1) BR112022002597A2 (cg-RX-API-DMAC10.html)
CA (1) CA3146701A1 (cg-RX-API-DMAC10.html)
CO (1) CO2022001450A2 (cg-RX-API-DMAC10.html)
IL (1) IL290482A (cg-RX-API-DMAC10.html)
JO (1) JOP20220014A1 (cg-RX-API-DMAC10.html)
MX (2) MX2022001741A (cg-RX-API-DMAC10.html)
TW (1) TWI870440B (cg-RX-API-DMAC10.html)
UA (1) UA130650C2 (cg-RX-API-DMAC10.html)
WO (1) WO2021030386A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3442977T3 (fi) * 2016-04-15 2023-09-26 Blueprint Medicines Corp Aktiviinireseptorin kaltaisen kinaasin estäjät
CA3117695A1 (en) 2018-10-26 2020-04-30 Keros Therapeutics, Inc. Crystal forms of an alk2 inhibitor
US12508262B2 (en) 2020-04-30 2025-12-30 Keros Therapeutics, Inc. Methods of using ALK2 inhibitors
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
WO2026161341A1 (en) * 2025-01-21 2026-07-30 Blueprint Medicines Corporation Drug product formulations of fidrisertib

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3442977T3 (fi) * 2016-04-15 2023-09-26 Blueprint Medicines Corp Aktiviinireseptorin kaltaisen kinaasin estäjät
AR112027A1 (es) * 2017-06-15 2019-09-11 Biocryst Pharm Inc Inhibidores de alk 2 quinasa que contienen imidazol

Also Published As

Publication number Publication date
TWI870440B (zh) 2025-01-21
KR20220052955A (ko) 2022-04-28
AU2020328534A1 (en) 2022-03-17
JP2022544272A (ja) 2022-10-17
JP2025148406A (ja) 2025-10-07
MX2022001741A (es) 2022-03-11
US20220281879A1 (en) 2022-09-08
WO2021030386A1 (en) 2021-02-18
EP4013757A1 (en) 2022-06-22
CN114222745A (zh) 2022-03-22
AU2020328534B2 (en) 2026-04-30
UA130650C2 (uk) 2026-04-08
BR112022002597A2 (pt) 2022-07-05
CN119638704A (zh) 2025-03-18
JP7775186B2 (ja) 2025-11-25
TW202120509A (zh) 2021-06-01
CO2022001450A2 (es) 2022-05-31
CN114222745B (zh) 2025-03-25
MX2024014312A (es) 2024-12-06
KR102967623B1 (ko) 2026-05-21
CA3146701A1 (en) 2021-02-18
IL290482A (en) 2022-04-01

Similar Documents

Publication Publication Date Title
IL289534A (en) Parp1 inhibitors
IL287940A (en) Fgfr inhibitors and methods of use thereof
IL284640A (en) Pcsk9 inhibitors and methods of use thereof
EP4087573A4 (en) Kras g12c inhibitors
MA54327A (fr) Inhibiteurs de kras g12c
IL292642A (en) Ras inhibitors
DK4051678T3 (da) Småmolekylære hæmmere af kras g12c mutant
IL287751A (en) Kcnt1 inhibitors and methods of use
IL287768A (en) Kcnt1 inhibitors and methods of use
EP4696316A3 (en) RAS INHIBITORS
EP3984999A4 (en) ALLOSTERIC INHIBITOR OF PHOSPHATASE SHP2
IL290482A (en) Salt and crystal forms of the activin receptor-like kinase inhibitor
EP3844151A4 (en) KRAS G12C INHIBITORS
IL283592A (en) Inhibitors of apol1 and methods of using same
IL288996A (en) Aminopyrimidine amide autophagy inhibitors and methods of use thereof
EP3801500A4 (en) Inhibitors of sarm1
SG11202010882XA (en) Salts of an fgfr inhibitor
DK4146348T3 (da) Inhibitorer af nek7-kinase
MX2020009887A (es) Derivados de aminopiridina como inhibidores de ctps1.
JOP20220054A1 (ar) علاج اعتلال الدماغ syngap1
MY204609A (en) Imidazole-containing inhibitors of alk2 kinase
HRP20251592T1 (hr) Inhibitori arginaze i metode njihove primjene
HRP20260295T1 (hr) Kristalni oblici inhibitora btk
EP3741752A4 (en) Tam family kinase /and csf1r kinase inhibitor and use thereof
JOP20200081A1 (ar) أملاح من مشتقات بيرولوتريازين مفيدة بوصفها مثبطات لـ tam